0001314052 2025-10-01 2025-12-31 0001314052 2026-02-09 shares true --09-30 2026 Q1 0001314052 10-Q/A true 2025-12-31 false 001-37606 ANAVEX LIFE SCIENCES CORP. NV 98-0608404 630 5th Avenue 20th Floor New York NY US 10111 844 689-3939 Common Stock Par Value $0.001 AVXL NASDAQ Yes Yes Large Accelerated Filer false false false 92671758 As previously disclosed in a Current Report on Form 8-K, filed with the Securities and Exchange Commission (“SEC”) on May 6, 2026, on April 30, 2026, a special committee (the “Special Committee”) composed of independent directors of the Board of Directors of the Company (the “Board”) terminated the employment of the Company’s former Chief Executive Officer (“CEO”) for Cause (as defined in the Employment Agreement, dated as of June 27, 2013, between the Company and its former CEO, as amended and restated), effective immediately for, among other things, conduct that the Special Committee believed was inconsistent with Company policy. As a result of the review by the Special Committee, management, in consultation with the Audit Committee of the Board (the “Audit Committee”), concluded that there was a material weakness in internal control over financial reporting that existed at September 30, 2025. Accordingly, the Company’s internal control over financial reporting as of December 31, 2025, as reported in its Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2025 (the “Original Form 10-Q”) were not effective. In addition, the Company’s disclosure controls and procedures were not effective as of December 31, 2025, due to the material weakness in internal control over financial reporting as described above.    The reassessment of the effectiveness of the Company’s disclosure controls and procedures and its internal control over financial reporting described above did not result in any misstatement in the Company’s previously issued condensed consolidated interim financial statements for the quarterly period ended December 31, 2025. As a result, the Company is not restating its condensed consolidated interim financial statements in this Amendment No. 1 (this “Amendment”) to the Original Form 10-Q.   The Company is filing this Amendment to amend the following:  ●Item 4. “Controls and Procedures” was amended to reflect ineffective disclosure controls and procedures and internal control over financial reporting as of December 31, 2025 as a result of the material weakness related to entity-level control deficiencies as described in the Company’s Form 10-K/A for the fiscal year ended September 30, 2025, (the “2025 Form 10-K/A”) filed with the SEC on August 28, 2026.   ●Item 6. “Exhibits” of the Original Form 10-Q is amended and restated to reflect the new certifications referenced below.   This Amendment also includes the following exhibits to replace exhibits previously filed:     ● new currently dated certifications (as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended), by the Company’s principal executive officer and principal financial officer.    Except as described in this Explanatory Note, this Amendment does not amend, modify or update disclosures included in the Original Form 10-Q, nor does it reflect events occurring after the filing of the Original Form 10-Q. Among other things, business-related disclosures, risk factors and forward-looking statements made in the Original Form 10-Q have not been revised to reflect events that occurred or facts that became known to the Company after the filing of the Original Form 10-Q, and any such statements should be read in their historical context. Accordingly, this Amendment should be read in conjunction with the Company’s filings with the SEC that were made subsequent to the filing of the Original Form 10-Q and this Amendment.